NCT01686555 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Lupus Erythematosus

Interventions

DRUG

ABT-199

Tablet

OTHER

Placebo

Tablet

Trial Locations (15)

10117

Site Reference ID/Investigator# 107896, Berlin

11030

Site Reference ID/Investigator# 89773, Manhasset

16635

Site Reference ID/Investigator# 78254, Duncansville

32713

Site Reference ID/Investigator# 131720, DeBary

32806

Site Reference ID/Investigator# 89693, Orlando

33016

Site Reference ID/Investigator# 124116, Miami Lakes

33136

Site Reference ID/Investigator# 118637, Miami

33765

Site Reference ID/Investigator# 89694, Clearwater

55905

Site Reference ID/Investigator# 129826, Rochester

66212

Site Reference ID/Investigator# 78256, Overland Park

75231

Site Reference ID/Investigator# 123335, Dallas

Site Reference ID/Investigator# 78253, Dallas

CP 14050

Site Reference ID/Investigator# 116395, Distrito Federal

C.P. 64000

Site Reference ID/Investigator# 112555, Monterrey

00909-3004

Site Reference ID/Investigator# 132009, San Juan

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY